Across TCGA pan-cancer cohorts, RNU6-316P RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated RNU6-316P data layer compared with 1 for mutation status.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RNU6-316P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-316P expression acts as an unfavorable survival marker, although some lineages such as TGCT and THYM show a favorable association.
LIHC, ACC, and UCS are the cancer types where RNU6-316P RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.